Increasing unusual call option volume: ALXN RFP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Alexion Pharmaceuticals (ALXN) PT Raised to $156 at Nomura/Instinet
March 15, 2018 1:45 PM EDTNomura/Instinet raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $156.00 (from $148.00) while maintaining a Buy rating.
Analyst Christopher Marai commented, "Alexion reported results from the P3 301 study of ALXN1210 in PNH-naïve patients. The study demonstrated non-inferiority across all co-primary and four key... More
Alexion Pharmaceuticals (ALXN) PT Raised to $160 at Baird
March 15, 2018 12:14 PM EDTBaird raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160.00 (from $150.00) while maintaining a Outperform rating.
Analyst Michael E. Ulz commented, "Following the call, we remain encouraged by the Phase 3 PNH naïve results with ALXN1210 demonstrating non-inferiority on all six key endpoints with... More
